"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
| Descriptor ID |
D017024
|
| MeSH Number(s) |
E02.186.170 E02.319.170
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 3 | 3 |
| 1995 | 0 | 4 | 4 |
| 1996 | 0 | 10 | 10 |
| 1997 | 0 | 8 | 8 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 4 | 4 |
| 2001 | 4 | 9 | 13 |
| 2002 | 2 | 3 | 5 |
| 2003 | 0 | 8 | 8 |
| 2004 | 2 | 9 | 11 |
| 2005 | 0 | 11 | 11 |
| 2006 | 0 | 9 | 9 |
| 2007 | 0 | 14 | 14 |
| 2008 | 2 | 18 | 20 |
| 2009 | 0 | 16 | 16 |
| 2010 | 0 | 17 | 17 |
| 2011 | 0 | 19 | 19 |
| 2012 | 0 | 13 | 13 |
| 2013 | 0 | 12 | 12 |
| 2014 | 5 | 5 | 10 |
| 2015 | 1 | 12 | 13 |
| 2016 | 1 | 15 | 16 |
| 2017 | 3 | 15 | 18 |
| 2018 | 0 | 19 | 19 |
| 2019 | 7 | 14 | 21 |
| 2020 | 2 | 5 | 7 |
| 2021 | 2 | 5 | 7 |
| 2022 | 1 | 9 | 10 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 8 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach. Breast Cancer Res. 2024 Oct 29; 26(1):148.
-
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Sep 28; 404(10459):1240-1252.
-
Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Ann Surg Oncol. 2024 Oct; 31(11):7420-7428.
-
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol. 2024 Nov; 42(31):3652-3665.
-
Editorial Comment on "Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer". Urology. 2024 Sep; 191:85.
-
Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). J Clin Oncol. 2024 Aug 20; 42(24):2853-2859.
-
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. Hepatol Commun. 2024 06 01; 8(6).
-
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial. JAMA. 2024 05 28; 331(20):1714-1721.
-
Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
-
Safety and feasibility of establishing an adjuvant hepatic artery infusion program. HPB (Oxford). 2024 05; 26(5):656-663.